Labrie F, Bélanger A, Cusan L, Candas B
Medical Research Council Group in Molecular Endocrinology, Centre Hospitalier de l'Universite Laval Research Center, Le Centre Hospitalier Universitaire de Québec, Canada.
J Clin Endocrinol Metab. 1997 Aug;82(8):2403-9. doi: 10.1210/jcem.82.8.4161.
This study analyzes in detail the serum concentration of the active androgens and estrogens, as well as a series of free and conjugated forms of their precursors and metabolites, after daily application for 2 weeks of 10 mL 20% dehydroepiandrosterone (DHEA) solution on the skin to avoid first passage through the liver. In men, DHEA administration caused 175%, 90%, 200% and 120% increases in the circulating levels of DHEA and its sulfate (DHEA-S), DHEA-fatty acid esters, and androst-5-ene-3 beta,17 beta-diol, respectively, with a return to basal values 7 days after cessation of the 14-day treatment. Serum androstenedione increased by approximately 80%, whereas serum testosterone and dihydrotestosterone (DHT) remained unchanged. In parallel with the changes in serum DHEA, the concentrations of the conjugated metabolites of DHT, namely androsterone glucuronide, androstane-3 alpha,17 beta-diol-G, and androstane-3 beta,17 beta-diol-G increased by about 75%, 50%, and 75%, respectively, whereas androsterone-sulfate increased 115%. No consistent change was observed in serum estrone (E1) or estradiol (E2) in men receiving DHEA, whereas serum E1-sulfate and E2-sulfate were slightly and inconsistently increased by about 20%, and serum cortisol and aldosterone concentrations were unaffected by DHEA administration. Almost superimposable results were obtained in women for most steroids except testosterone, which was about 50% increased during DHEA treatment. This increase corresponded to about 0.8 nM testosterone, an effect undetectable in men because they already have much higher (approximately 15 nM) basal testosterone levels. In women, the serum levels of the conjugated metabolites of DHT, namely androsterone glucuronide, androstane-3 alpha,17 beta-diol-G, androstane-3 beta,17 beta-diol-G, and androsterone-sulfate were increased by 125%, 140%, 120% and 150%, respectively. The present study demonstrates that the serum concentrations of testosterone, DHT, E1, and E2 are poor indicators of total androgenic and estrogenic activity. However, the esterified metabolites of DHT appear as reliable markers of the total androgen pool, because they directly reflect the intracrine formation of androgens in the tissues possessing the steroidogenic enzymes required to transform the inactive precursors DHEA and DHEA-S into DHT. As well demonstrated in women, who synthesize almost all their androgens from DHEA and DHEA-S, supplementation with physiological amounts of exogeneous DHEA permits the biosynthesis of androgens limited to the appropriate target tissues without leakage of significant amounts of active androgens into the circulation. This local or intracrine biosynthesis and action of androgens eliminates the inappropriate exposure of other tissues to androgens and thus minimizes the risks of undesirable masculinizing or other androgen-related side effects of DHEA.
本研究详细分析了在皮肤上每日涂抹10 mL 20%脱氢表雄酮(DHEA)溶液2周后活性雄激素和雌激素的血清浓度,以及它们的一系列前体和代谢物的游离和结合形式,以避免首过肝脏效应。在男性中,给予DHEA导致循环中DHEA及其硫酸盐(DHEA-S)、DHEA-脂肪酸酯和雄甾-5-烯-3β,17β-二醇的水平分别升高175%、90%、200%和120%,在14天治疗停止后7天恢复至基础值。血清雄烯二酮增加约80%,而血清睾酮和双氢睾酮(DHT)保持不变。与血清DHEA的变化同时,DHT的结合代谢物,即雄酮葡萄糖醛酸苷、3α,17β-雄烷二醇葡萄糖醛酸苷和3β,17β-雄烷二醇葡萄糖醛酸苷的浓度分别增加约75%、50%和75%,而硫酸雄酮增加115%。接受DHEA的男性血清雌酮(E1)或雌二醇(E2)未观察到一致变化,而血清E1-硫酸盐和E2-硫酸盐略有且不一致地增加约20%,血清皮质醇和醛固酮浓度不受DHEA给药影响。在女性中,除睾酮外,大多数类固醇获得了几乎重叠的结果,睾酮在DHEA治疗期间增加约50%。这种增加相当于约0.8 nM睾酮,在男性中无法检测到这种效应,因为他们的基础睾酮水平已经高得多(约15 nM)。在女性中,DHT的结合代谢物,即雄酮葡萄糖醛酸苷、3α,17β-雄烷二醇葡萄糖醛酸苷、3β,17β-雄烷二醇葡萄糖醛酸苷和硫酸雄酮的血清水平分别增加125%、140%、120%和150%。本研究表明,睾酮、DHT、E1和E2的血清浓度并非总雄激素和雌激素活性的良好指标。然而,DHT的酯化代谢物似乎是总雄激素池的可靠标志物,因为它们直接反映了在具有将无活性前体DHEA和DHEA-S转化为DHT所需的类固醇生成酶的组织中雄激素的内分泌形成。正如在几乎所有雄激素都由DHEA和DHEA-S合成的女性中所充分证明的那样,补充生理量的外源性DHEA可使雄激素的生物合成限于适当的靶组织,而不会有大量活性雄激素泄漏到循环中。雄激素的这种局部或内分泌生物合成及作用消除了其他组织对雄激素的不适当暴露,从而将DHEA不期望的男性化或其他雄激素相关副作用的风险降至最低。